We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Intravenous Alteplase Raises Ischemic Stroke Survival

By HospiMedica International staff writers
Posted on 31 Oct 2017
Print article
Image: A new study suggests the administration of intravenous alteplase can save stroke victims lives (Photo courtesy of 123rf).
Image: A new study suggests the administration of intravenous alteplase can save stroke victims lives (Photo courtesy of 123rf).
A new study also warns that ischemic stroke patients who do not receive intravenous (IV) alteplase are significantly less likely to survive.

Researchers at Georgia State University (GSU; Atlanta, USA), the Georgia Department of Public Health (Atlanta, USA), and other institutions reviewed the 2008–2013 Georgia Coverdell Acute Stroke Registry data, which was then linked with 2008–2013 hospital discharge records and 2008–2014 death data in the state of Georgia (USA). The aim of the study was to assess the impact of thrombolytic treatment by IV alteplase on one-year mortality and readmission rates among acute ischemic stroke patients.

The results revealed that that 9,620 people underwent acute ischemic stroke during the study period. Of these, 20.3% of patients died and 22.4% were readmitted within the year. Analysis showed that patients who did not receive IV alteplase had a 49% higher risk of dying at one year than those who were treated with the thrombolytic agent. Among patients who were discharged, no statistically significant difference was documented in the odds of being readmitted at least once within 365 days of post-stroke discharge. The study was published on July 31, 2017, in the American Journal of Emergency Medicine.

“Clinicians may be hesitant to administer IV alteplase because of concerns about the drug's complications, which can include bleeding,” said lead author Moges Ido, MD, of GSU. “But this study indicates that unless major contraindications are present, patients should be offered this treatment as a life-saving measure.”

IV alteplase administered within 4.5 hours of symptom onset is the only reperfusion therapy with proven efficacy in patients with acute ischemic stroke. However, well-recognized limitations of this therapy include the narrow therapeutic time window and contraindications such as recent surgery, coagulation abnormalities, and a history of intracranial hemorrhage. Moreover, IV alteplase appears to be much less effective at opening proximal occlusions of the major intracranial arteries, which account for more than one-third of cases of acute anterior-circulation stroke.

Related Links:
Georgia State University
Georgia Department of Public Health

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Video Laryngoscope
SH-VL1

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.